Catalent Inc (NASDAQ:CTLT) was upgraded by TheStreet from a “c” rating to a “b-” rating in a report released on Wednesday.
Other equities analysts also recently issued research reports about the company. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a research report on Tuesday, April 11th. Jefferies Group LLC raised their price target on Catalent from $29.00 to $32.00 and gave the stock a “hold” rating in a research report on Monday, February 27th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Catalent currently has a consensus rating of “Buy” and a consensus price target of $29.50.
Shares of Catalent (NASDAQ:CTLT) traded down 0.78% on Wednesday, hitting $28.07. The stock had a trading volume of 181,807 shares. Catalent has a one year low of $20.94 and a one year high of $30.28. The firm’s 50-day moving average is $28.38 and its 200-day moving average is $26.53. The company has a market cap of $3.50 billion and a price-to-earnings ratio of 39.04.
Catalent (NASDAQ:CTLT) last released its quarterly earnings results on Monday, February 6th. The company reported $0.27 earnings per share for the quarter, hitting the consensus estimate of $0.27. The company had revenue of $483.70 million for the quarter, compared to analysts’ expectations of $474.07 million. The business’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.36 EPS. On average, analysts expect that Catalent will post $1.39 EPS for the current fiscal year.
In other Catalent news, insider John R. Chiminski sold 73,819 shares of the firm’s stock in a transaction on Monday, March 20th. The stock was sold at an average price of $28.62, for a total transaction of $2,112,699.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Donald E. Morel, Jr. purchased 10,000 shares of the company’s stock in a transaction on Wednesday, February 15th. The shares were bought at an average cost of $29.27 per share, with a total value of $292,700.00. The disclosure for this purchase can be found here.
Institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its stake in shares of Catalent by 62.6% in the third quarter. PNC Financial Services Group Inc. now owns 3,908 shares of the company’s stock worth $101,000 after buying an additional 1,504 shares in the last quarter. Advisor Group Inc. increased its stake in shares of Catalent by 93.9% in the third quarter. Advisor Group Inc. now owns 5,277 shares of the company’s stock worth $134,000 after buying an additional 2,556 shares in the last quarter. Elkfork Partners LLC acquired a new stake in shares of Catalent during the fourth quarter worth approximately $176,000. LS Investment Advisors LLC increased its stake in shares of Catalent by 5.2% in the third quarter. LS Investment Advisors LLC now owns 7,499 shares of the company’s stock worth $194,000 after buying an additional 368 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new stake in shares of Catalent during the third quarter worth approximately $219,000.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.